Mutational K-ras activation arises very frequently in epithelial cancers, with highest frequencies prevalent in lung, pancreatic and colorectal cancers. K-ras mutant cancers are highly aggressive with extremely poor prognoses and high mortality rates. Unfortunately, these cancers remain highly refractory to both conventional and targeted therapeutics. Additionally, pharmacological inhibition of K-Ras protein has proven to be difficult to achieve clinically. My initial aim was to model """"""""addiction"""""""" to mutant K-ras in the hopes of identifying molecular determinants that define the """"""""Kras-addicted"""""""" state with the ultimate aim of identifying candidate therapeutic targets. Using K-ras-specific shRNAs to deplete K-Ras protein in lung and pancreatic cancer cell lines harboring mutant K-ras, I identified two classes - those that are """"""""addicted"""""""" to or dependent on K- Ras activity for viability and those that are K-Ras independent. By comparing whole genome expression profiles for these two classes, I derived a gene expression signature associated with K-Ras dependency. Several genes represented in this signature were required to maintain the viability of K-Ras dependent cancer cells, implicating them as candidate therapeutic targets in Kras mutant cancers. This proposal hopes to extend these initial findings by identifying lineage or tissue-specific anti-apoptotic genes in Kras mutant cancers, with the hopes of revealing novel context-specific therapeutic targets. Tissue-specific K-Ras dependency signatures will be generated for Kras mutant lung, pancreatic and colorectal cancers. Genes representing pharmacologically tractable targets will then be validated for their potential as candidate therapeutic targets. Cell biological and biochemical analyses will be performed to determine if there are tissue-specific biological or signaling features that contribute to the general phenomenon of K-Ras dependency. Finally, available pharmacological inhibitors against these targets will be tested for efficacy in pre-clinical mouse models of K-ras-driven tumorigenesis.

Public Health Relevance

Kras is the most frequently mutated oncogene in solid tumors with highest frequencies seen in lung, pancreatic and colorectal cancers. I propose to generate gene expression signatures for lung, pancreatic and colorectal cancers in the hopes of identifying novel therapies for each of these cancers, which are very difficult to treat with current chemotherapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Career Transition Award (K99)
Project #
5K99CA149169-02
Application #
8088161
Study Section
Subcommittee G - Education (NCI)
Program Officer
Schmidt, Michael K
Project Start
2010-06-08
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
2
Fiscal Year
2011
Total Cost
$135,653
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Grant, Trevor J; Mehta, Anita K; Gupta, Anamika et al. (2017) STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget 8:78556-78572
Mehta, Anita K; Hua, Kevin; Whipple, William et al. (2017) Regulation of autophagy, NF-?B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal 10:
Grant, T J; Hua, K; Singh, A (2016) Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci 144:241-275
Javaid, Sarah; Zhang, Jianmin; Smolen, Gromoslaw A et al. (2015) MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Mol Cancer Res 13:934-43
Brandl, Miriam B; Pasquier, Eddy; Li, Fuhai et al. (2014) Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol 8:1548-60
Wang, Meng; Kern, Ashley M; Hülskötter, Marieke et al. (2014) EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res 74:2825-34
Sahin, Ozgur; Wang, Qingfei; Brady, Samuel W et al. (2014) Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res 24:542-59
Liu, Suling; Cong, Yang; Wang, Dong et al. (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2:78-91
Glasgow, Stacey M; Laug, Dylan; Brawley, Vita S et al. (2013) The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci 33:13560-8
Li, Fuhai; Yin, Zheng; Jin, Guangxu et al. (2013) Chapter 17: bioimage informatics for systems pharmacology. PLoS Comput Biol 9:e1003043

Showing the most recent 10 out of 23 publications